Brain tumors are associated with genetic alterations of oncogenes and tumor suppressor genes. Accumulation of reactive oxygen species (ROS) in cells leads to oxidative stress-induced damage, resulting in tumorigenesis. Here, we showed that the nuclear matrix protein nuclear restricted protein in brain (NRP/B) was colocalized and interacted with NF-E2-related factor 2 (Nrf2). During oxidative stress response, NRP/B expression and its interaction with Nrf2 were upregulated in SH-SY5Y cells. Association of NRP/B with Nrf2 was crucial for NAD(P)H:quinone oxidoreductase 1 (NQO1) expression. NRP/B was localized predominantly in the nucleus of normal brain cells, whereas in primary brain tumors NRP/B was almost exclusively contained in the cytoplasm. In addition, unlike wild-type NRP/B, the expression of NRP/B mutants isolated from primary brain tumors was found in the cytoplasm, and these mutants failed to induce Nrf2-dependent NQO1 transcription. Thus, NRP/B mutations and their altered localization resulted in changes in NRP/B function and deregulation of Nrf2-dependent NQO1 activation in brain tumors. This study provides insights into the mechanism by which the NRP/B modulates Nrf2-dependent NQO1 induction in cellular protection against ROS in brain tumors.
Introduction
Nuclear matrix proteins are involved in multiple biological processes such as transcription, cell cycle and primary transcription processing, and are also linked to intermediate filaments of the cytoskeleton (He et al., 1995; Loidl and Eberharter, 1995) . These proteins have been implicated in malignant transformation (Fey and Penman, 1984; Getzenberg et al., 1996) , such as alterations in DNA ploidy, DNA content, nuclear shape and proliferative states (Berezney et al., 1995) . The nuclear matrix protein termed nuclear restricted protein in brain (NRP/B) (Kim et al., 1998) , also known as ENC-1 (Hernandez et al., 1997) , was characterized as a Kelch-related protein. The protein consists of two main domains, BTB (Broad-complex, Tramtrack, Bric-a-brac) and Kelch repeats. The BTB domain is implicated in protein-protein interactions (Bardwell and Treisman, 1994) . The Kelch repeats, consisting of about 50 amino acids, is involved in binding actin, protein folding and protein-protein interactions (Bardwell and Treisman, 1994) . NRP/B has been shown to be expressed in neurons, but not in normal glia cells (Kim et al., 1998) , and to play important roles in neuronal differentiation (Kim et al., 1998 (Kim et al., , 2000 and in the development of the central nervous system (Kim et al., 1998) . In cancer, NRP/B has been implicated in malignant transformation in the human nervous system (Hernandez et al., 1998) , human glioblastoma tumors (Liang et al., 2004) , colorectal carcinomas (Fujita et al., 2001) and hairy cell leukemia (Hammarsund et al., 2004) .
Reactive oxygen species (ROS) are physiologically produced during cellular metabolism. However, imbalances between the generation and clearance of ROS result in their intracellular accumulation, which induces oxidative stress and causes lipid peroxidation, DNA oxidation and carbonylation, leading to impairment in the function of lipids, DNA and proteins (Dalton et al., 1999; Andreassi, 2003) . The pathological consequences subsequently result in cellular inflammation and cancer (Venugopal and Jaiswal, 1996; Wasserman and Fahl, 1997; Itoh et al., 1999; Nguyen et al., 2003) . Cells have evolved defense mechanism(s) to survive their exposure to the cellular environment. One of these mechanisms is mediated by a basic leucine zipper transcription factor pathway involving NF-E2-related factor 2 (Nrf2). Under homeostatic conditions, Kelch-like ECH-associated protein (Keap1) functions as a transcriptional repressor by sequestering Nrf2 in the cytoplasm (Wakabayashi et al., 2004) . Under oxidative stressinduced conditions, the Keap1-Nrf2 interaction is destabilized and Nrf2 translocates to the nucleus and binds to antioxidant response element (ARE) sites in the promoter regions of many detoxifying and antioxidant genes (Wakabayashi et al., 2004; Lee and Johnson, 2005) . This leads to coordinated upregulation of downstream targets that boost cellular detoxification processes and antioxidant potential, such as that of NAD(P)H:quinone oxidoreductase 1 (NQO1) (Wakabayashi et al., 2004; Lee and Johnson, 2005) . Nrf2 interacts with NRP/B in the nucleus, and this interaction is required for the activation of Nrf2-mediated NQO1 (Seng et al., 2007) . NQO1 provokes cellular defense against ROS and inhibits neoplasia (Nioi and Hayes, 2004) . Induction of NQO1 provides multiple levels of cellular protection through its catalytic activity, such as maintenance of endogenous antioxidants in their reduced and active forms and regulation of the stability of the p53 tumor suppressor protein and apoptosis in human and mouse cells (Asher et al., 2001; Long et al., 2002) . Furthermore, NQO1 is involved in cancer prevention as part of some anticancer drugs (Riley and Workman, 1992; Begleiter et al., 1997) .
A frequent incidence of malignancy of the CNS has been observed in children and adults (Maher et al., 2001; Wechsler-Reya and Scott, 2001; Louis et al., 2002) . Malignant glioblastomas (glioblastoma multiforme (GBM)), arising from astrocytes or astrocyte progenitors, are the most commonly observed neoplasms. We reported earlier that mutations within NRP/B were associated with brain tumors by promoting cell growth, attenuating caspase activation and suppressing p53-induced apoptosis (Liang et al., 2004) . In addition, wildtype NRP/B modulated the activation of Nrf2-mediated NQO1 in response to oxidative stress in breast cancer (Seng et al., 2007) .
In the present study, we demonstrate that NRP/B plays an important role in modulating Nrf2-mediated NQO1 induction. NRP/B mutants isolated from human primary glioblastoma tumors failed to induce the NQO1 transcription. The failure of Nrf2-mediated NQO1 activation was due to inactivation and/or altered localization of NRP/B. Furthermore, the present study defines the molecular mechanism by which NRP/B elicits Nrf2-mediated cellular defense against not only ROS-induced but also proinflammatory damages in brain tumors.
Results

Effects of NRP/B and Keap1 expression on Nrf2 localization
Under homeostatic conditions, the activity of Nrf2 transcription factor is repressed by Keap1 in cytoplasmic compartment, whereas in stressful conditions, Nrf2 is released and translocated to the nucleus (Itoh et al., 1999) , where it is colocalized with NRP/B (Seng et al., 2007) . Here, we examined whether there is any effect of forced expression of Keap1 or NRP/B on the localization of Nrf2. Cells were transfected with EGFP-Nrf2 alone or in combination with DsRed-Keap1 or with Myc-NRP/B. To distinguish the cytoplasmic and the nuclear compartments, cells were stained with F-actin and DAPI (4,6-diamidino-2-phenylindole). Furthermore, cells transfected with Myc-NRP/B were stained with anti-Myc antibody and subsequently with fluorescein isothiocyanate-conjugated mouse antibody. As shown in Figure 1a , Nrf2 expression was accumulated exclusively in the nucleus of EGFP-Nrf2-transfected cells. Nrf2 expression was localized in the cytoplasm of cells when EGFP-Nrf2 was co-transfected with DsRedKeap1 (Figure 1b) . When cells were co-transfected with EGFP-Nrf2 and Myc-NRP/B, Nrf2 was colocalized with NRP/B in the nucleus where NRP/B was expressed (Figure 1c ). These results indicated that whereas Keap1-Nrf2 colocalization was a result of Keap1 expression, colocalization of Nrf2-NRP/B was a result of Nrf2 translocation to the nucleus.
Localization and interaction of NRP/B with Nrf2
We reported earlier that NRP/B protein is expressed in rat primary hippocampal neurons, but not in primary astrocytes (Kim et al., 1998) . Furthermore, NRP/B expression was upregulated during the differentiation of human neuroblastoma SH-SY5Y cells (Kim et al., 1998) . Thus, for this study we utilized human neuroblastoma SH-SY5Y cells. SH-SY5Y cells were grown on glass slides and stained with anti-NRP/B (VD2), control IgG antibody and DAPI as indicated in Figure 2a . To confirm the nuclear localization of NRP/B, cytoplasmic and nuclear extraction were performed in SH-SY5Y cells using NE-PER nuclear and cytoplasmic extraction reagents. Cellular extracts were subjected to western blot analyses using anti-NRP/B (VD2), anti-lamin B1 (nuclear marker) and anti-GAPDH (cytoplasmic marker) antibodies. NRP/B expression was strongly observed in the nuclear extract ( Figure 2b ). Next, we examined the in vitro and in vivo interaction of NRP/B with Nrf2. HEK293T cells were transfected with NRP/ B:WT (Myc-tagged). A pull-down assay was performed using glutathione S-transferase (GST) or GST-Nrf2 as a bait. Cell extracts were incubated with GST or GSTNrf2. Complex of NRP/B and Nrf2 was subjected to western blotting with anti-Myc antibody. It was shown that NRP/B interacted with Nrf2 ( Figure 2c) . A similar association of Nrf2 with endogenous NRP/B in SH-SY5Y cells was observed by pull-down assay using anti-NRP/B antibody (VD2) (Figure 2d ), indicating that NRP/B colocalized and interacted with Nrf2 in vitro and in vivo.
Effect of NRP/B-Nrf2 complex on ARE promoter activity During oxidative stress, Nrf2 translocates to the nucleus and binds to ARE in the promoter regions of antioxidant genes and activates them (Wakabayashi et al., 2004; Lee and Johnson, 2005) . The ARE-Ti-luc promoter was used to examine the effect of the NRP/BNrf2 complex on ARE promoter activity. COS7 cells were co-transfected with ARE-Ti-luc promoter and mock, Nrf2, NRP/B, Keap1 or GFP (control) as indicated ( Figure 2e) . Following 24 h of transfection, cell lysates were prepared and luciferase activity was measured. Relative luciferase activity was up to sixfold higher in COS7 cells transfected with NRP/B when compared with cells transfected with mock, GFP or Keap1 (Figure 2e ). To validate the effects of these molecules on ARE promoter activity, we also examined the expression of the transfected DNA constructs in cells by western blot using anti-Nrf2, anti-NRP/B, anti-GFP, anti-Keap1 or anti-actin antibody (Figure 2e) . Data obtained here demonstrate that the NRP/B-Nrf2 complex was important in modulating ARE promoter activity.
Upregulation of NRP/B and Nrf2 expression by oxidative stress agents For these studies, the effects of NO donors (sodium nitroprusside; SIN-1, 3-morpholinosydonime; DETA-NO, diethylenetriamine nitric oxide adduct) and hydrogen oxygenase (H 2 O 2 ) on NRP/B expression were tested in human neuroblastoma SH-SY5Y cells. SH-SY5Y cells were treated with these oxidative stress agents. To optimize the concentration of these chemicals, SH-SY5Y cells were grown onto 96-well plates and treated with various amounts of the chemicals for 12 h. Cell viability was then assessed by using the CellTiter NonRadioactive Cell Proliferation Assay. For this purpose, chemical concentrations that are considered as optimal should have no significant effect on cell proliferation (Seng et al., 2007) . After 12 h, cell extracts were prepared and immunoprecipitated with anti-NRP/B antibody (VD2) or control IgG. The precipitates were then blotted and probed with anti-NRP/B antibody (VD2). Expression of NRP/B was upregulated on the H 2 O 2 treatment as compared with non-treated control (Figure 3a) . Treatment of cells with sodium nitroprusside, SIN-1 and DETA-NO showed no effect on NRP/B expression (data not shown) in agreement with our previous report (Seng et al., 2007) . These results indicated that H 2 O 2 specifically upregulated expression of NRP/B in SH-SY5Y cells.
On oxidative stress condition, Nrf2 is translocated into the nucleus and activated its target genes (Itoh et al., 1999) . Here, we examined the nuclear expression of Nrf2 during stress induction. SH-SY5Y cells were treated with H 2 O 2 for 12 h. Nuclear protein extraction was performed and subjected to western blotting using anti-Nrf2 antibody. The levels of Nrf2 expression were compared between cells treated with and without H 2 O 2 . Nuclear and cytoplasmic extracts were analysed by western blotting using anti-NRP/B (VD2), anti-lamin B1, anti-GAPDH or anti-CSK antibodies. Lamin B1 served as a nuclear marker. GAPDH was used as the cytoplasmic marker. CE: cytoplasmic extract; NE: nuclear extract. (c) Association of NRP/B with Nrf2. HEK293T cells were transfected with NRP/B:WT (tagged with Myc). After 24 h, pull-down assay was performed. Cell extracts were incubated with GST or GST-Nrf2. The complexes were then probed with anti-Myc antibody. To ensure equal loading and expression, the cell extracts were analysed by western blotting using anti-Myc antibody. (d) Interaction of NRP/B with Nrf2 in SH-SY5Y cells. Cell extracts were prepared from SH-SY5Y cells and incubated with GST or GST-Nrf2. Complexes were analysed by western blotting using anti-NRP/B antibody (VD2). To ensure equal loading, the cell extracts were western-blotted with anti-actin antibody. (e) Effect of NRP/B-Nrf2 complexes on ARE promoter activity. COS7 cells were co-transfected with ARE-Ti-luc promoter and Nrf2 in conjunction with NRP/B:WT, GFP, Keap1 or control mock. Following 24 h, cell extracts were prepared and ARE-Ti-luc promoter activity was measured. Relative luciferase (derived from three individual experiments) versus b-gal activity was expressed in arbitrary units. The bars in the graphs represent the mean ± s.d. **Po0.01. Cell extracts were blotted with anti-Nrf2, anti-NRP/B (VD2), anti-GFP, anti-Keap1 and anti-CSK antibodies to confirm the expression levels. Actin served as an internal control.
As shown in Figure 3b , nuclear levels of Nrf2 were increased in H 2 O 2 -treated SH-SY5Y cells as compared with untreated cells. After 12 h, cell extracts (500 mg) were then subjected to immunoprecipitation with IgG or anti-NRP/B (VD2) antibody, and blotting with VD2 antibody. For equal loading control, cell extracts were blotted with anti-actin antibody. Relative levels of NRP/B expression derived from three independent experiments were converted into arbitrary units. (Figure 3e ). These data showed that H 2 O 2 induced sequentially NQO1 promoter activity and transcription in SH-SY5Y cells.
Localization of NRP/B in normal brain and primary brain tumors
To compare the localization of NRP/B in normal brain and brain tumor specimens, glioblastoma multiforme (GBM) and normal frontal cortex specimens were obtained from the Cooperative Human Tissue Network and Beth Israel Deaconess Medical Center. The GBM was diagnosed by neuropathologists. Three normal brain specimens (NB 1-3) and three brain tumor specimens (BT 1-3) (representative of 10 brain tumors) were used for this study. These brain specimens were sectioned and stained with anti-NRP/B antibody (VD2) and hematoxylin and eosin. Localization of NRP/B was observed in the nucleus in normal brain specimens (NB 1-3) as indicated by hematoxylin staining (Figure 4a) . However, the expression of NRP/B was diffused to the cytoplasm in brain tumor specimens (BT 1-3), as indicated by hematoxylin and eosin staining (Figure 4a ). These results suggested that alteration in the localization of NRP/B may be related to its mutation in brain tumor specimens as reported earlier (Liang et al., 2004) . (Figure 5a ). We also compared the percentage of cytoplasmic and nuclear expression of these NRP/B wild type and mutants. Using a confocal microscope, 300 cells expressing NRP/B from each group of three individual experiments were randomly counted, and their cytoplasmic and nuclear expression ratios were determined as shown in Figure 5b . Taken together, these results showed that NRP/B:WT was expressed mainly in the nucleus, whereas the expression of these NRP/B mutants was mainly in the cytoplasm. Furthermore, NRP/B localization was similar to those observed in normal brains and primary brain tumors accordingly (Figure 4a ).
Effect of NRP/B mutations on Nrf2-mediated NQO1 transcriptional activity
The NQO1 promoter was co-transfected with NRP/ B:WT, NRP/B:NSQR, NRP/B:EKCR, or mock in conjunction with Nrf2 in SH-SY5Y, HEK293T and COS7 cells as indicated (Figure 6a ). NRP/B:WT and DsRed-Keap1 served as positive and negative controls, respectively. Following 24 h of transfection, total cell lysates were prepared and luciferase activity was measured. A significant increase in relative NQO1 promoter activity was found in cells co-transfected with Nrf2 and NRP/B:WT, whereas DsRed-Keap1 inhibited the activity, as expected (Figure 6a ). NRP/B:NSQR and NRP/B:EKCR mutants did not enhance NQO1 promoter activity as compared with the mock (control). To ensure equal loading and expression levels, the cell extracts were subjected to western blot analysis using anti-Nrf2, anti-NRP/B (VD2), anti-Keap1 and anti-CSK antibodies, as shown in the lower panels ( Figure 6a ). These data suggest that NRP/B mutants lost their capacity to modulate the Nrf2-mediated activation of NQO1.
Nuclear and cytoplasmic NRP/B expressions differentially affect the Nrf2-mediated NQO1 transcriptional activity As NRP/B is a nuclear matrix protein, it is expressed in the nucleus under physiologically normal conditions (Kim et al., 1998) . However, in primary brain tumors, NRP/B localization was diffused and shifted to the cytoplasm (Figure 4a) , and the NRP/B mutants derived from the primary brain tumors were mainly expressed in cytoplasm ( Figure 5 ). Here, we investigated whether the alteration of subcellular localization of NRP/B was associated with its failure to induce Nrf2-mediated NQO1 transcriptional activity. For this study, we compared the effects of the cytoplasmic and nuclear expression of NRP/B on the Nrf2-mediated induction of 
Discussion
In the present study, we report that NRP/B was involved in the activation of Nrf2-mediated NQO1 transcriptional activity in response to oxidative stress, and NRP/B mutants isolated from human primary brain tumors failed to induce NQO1 transcription through Nrf2 pathway. This failure resulted from mutation-induced alterations in NRP/B function and/or subcellular localization. This study has delineated the biological function and molecular mechanism of NRP/B in eliciting NQO1-mediated cellular defenses against ROS-induced damage in brain tumors. Both NRP/B and Keap1 are members of the Kelch protein family. These two proteins have a similarity in their protein structures and ability to bind to actin. Furthermore, these two proteins share an important feature in Nrf2 pathway, regulating detoxifying and antioxidant proteins (Itoh et al., 1999; Seng et al., 2007) . Under physiological conditions, Keap1 appears to repress Nrf2 activity by detaining it in the cytoplasm (Itoh et al., 1999) . Under oxidative stress stimuli, Nrf2 translocates and interacts with NRP/B in the nucleus resulting in the activation of detoxifying and antioxidant proteins (Itoh et al., 1999) . Forced expression of Keap1 sequestered Nrf2, and both molecules were colocalized in the cytoplasm. Nrf2 was localized in the nucleus when cells were transfected with EGFP-Nrf2 alone. Coexpression of EGFP-Nrf2 with Myc-NRP/B showed that Nrf2 was localized in the nucleus and colocalized with NRP/B (Figure 1 ). Data obtained here suggest that Keap1 is the cytoplasmic attractor for Nrf2, whereas NRP/B is a nuclear acceptor for Nrf2 when it is released by Keap1. Thus, Nrf2 interaction with Keap1 in the cytoplasm resulted in a negative effect on Nrf2-dependent NQO1, whereas Nrf2 association with NRP/B was the result of its translocation to the nucleus and led to the induction of Nrf2-dependent NQO1 (Figures 2, 4 and 6 ). These findings suggest that the movement of Nrf2 to the nucleus, and its subsequent interaction with nuclear NRP/B, is a crucial step in Nrf2-mediated activation of downstream target gene(s), and that proper localization of cytoplasmic Keap1 and nuclear NRP/B allows for modulation of Nrf2 function in the context of oxidative stress responses in human brains.
NRP/B mutations impair Nrf2-dependent NQO1 induction S Seng et al
During oxidative stress responses, association of Nrf2 with NRP/B in the nuclear compartment was crucial in eliciting NQO1 transcription. NRP/B expression was observed exclusively in the nucleus of normal brain specimens, whereas it was expressed prominently in the cytoplasm of brain tumor specimens (Figure 4) . To address the question whether the nucleus-to-cytoplasm localization of NRP/B is associated with its mutations, we isolated NRP/B mutants from human primary brain tumors and expressed them in cell lines. Confocal microscopy revealed that wild-type NRP/B was localized in the nucleus, whereas the majority of NRP/B mutants were observed in the cytoplasm ( Figure 5 ). NRP/B consists of actin-binding domain termed Kelch domain. In both NRP/B mutants isolated from the primary brain tumors, the mutations occurred in the Kelch domain (Figure 4b ), and their interactions with actin were reduced (data not shown) in agreement with our previous report (Liang et al., 2004) . Therefore, the reduction in actin-binding affinity of NRP/B mutants in brain tumor specimens may lead to a shift of NRP/B localization in cells. On the other hand, the mutations within NRP/B may result in altered NRP/B conformation leading to deregulation of NRP/B-Nrf2 complexes.
The subcellular localization of a given protein is critical for its signaling pathway and function. NRP/B mutants were unable to induce Nrf2-mediated NQO1 transcription due to alteration of their localization and functionality (Figures 4 and 6) . To investigate the differential effects of cytoplasmic and nuclear localizations of NRP/B on NQO1 activation, wild-type NRP/B constructs were designed to target its expression in either the cytoplasmic or nuclear compartment using nuclear localization signal. Wild-type NRP/B:WT was mainly expressed in the nucleus and activated Nrf2-mediated NQO1 transcriptional activity and expression (Figures  4-6) , whereas wild-type NRP/B:WT/Cyt was exclusively expressed in the cytosol and failed to activate NQO1 transcriptional activity and expression (Figures 4-6) . Thus, these results suggest that the altered localization of the NRP/B mutants from the nucleus to the cytosol affected the activation of Nrf2-mediated NQO1 transcription, subsequently rendering brain cells susceptible to oxidative stress-induced damage, which may be associated with brain tumors.
Nuclear matrix proteins have been implicated in the regulation of gene expression, the cell cycle and in the integrity of the nuclear structure (Bode et al., 2000) . Nuclear structural alterations are prevalent in cancer cells and commonly used as pathological markers of transformation in many types of cancers (Konety and Getzenberg, 1999; Saunders et al., 2000) . Changes in the nuclear structural framework may result in the transformation of normal cells to a malignant state by affecting transcription, replication and/or other nuclear processes (Konety and Getzenberg, 1999; Alberti et al., 2000) . Aberrations in nuclear matrix proteins often contribute to tumors. Alterations and mutations of NRP/B promoted cell growth, attenuated caspase activation and suppressed p53-mediated apoptosis (Liang et al., 2004) . NQO1 provided the cells with multiple steps of protection against those toxic insults through several proposed mechanisms: direct catalytic actions, indirect antioxidant functions or stabilization of p53 protein in response to DNA-damaging stimuli, thereby influencing cell fate (Nioi and Hayes, 2004) . Under oxidative stress conditions, p53 stabilization is mediated by NQO1 as NQO1-p53 interaction protects p53 degradation. In response to oxidative stress stimuli, Nrf2 interacted with NRP/B and subsequently resulted in the induction of NQO1 in response to oxidative stress damage ( Figures 3, 4 and 6 ). These findings suggested that NRP/B might be involved in the process of p53 stabilization by modulating Nrf2-dependent NQO1 in tumors.
Moreover, forced expression of wild-type NRP/B in conjunction with Nrf2 induced NQO1 promoter activity and increased transcription levels of NQO1 (Figures 4  and 6 ). H 2 O 2 increased the levels of NRP/B and NQO1 expression (Figure 3) . The p53 accumulation by NQO1 was more prominent after the induction of oxidative stress by H 2 O 2 (Asher et al., 2002) . Thus, NRP/B might modulate p53 stabilization indirectly through upregulation of NQO1 expression levels, thereby leading to an increased level of NQO1 interacting with p53, which protects p53 from degradation. The failure of NRP/B mutants to induce NQO1 or/and deregulation of NRP/B may therefore contribute to impairment of NQO1-mediated p53 stabilization and consequently may lead to brain tumors.
Under oxidative stress conditions, translocation of Nrf2 is required to induce ARE-driven genes (NQO1, heme oxygenase 1 (HO1), GSTs and glutamate cysteine ligase (GCL)) in cells (Lee and Johnson, 2005) . Nrf2-NRP/B complex induced ARE-driven promoter activity (Figure 2) . Additionally, we also observed that the Nrf2-NRP/B complex enhanced ARE-driven HO1-transcriptional activity and NRP/B mutants failed to support Nrf2-dependent HO1 transcriptional activity (data not shown). These data provide a foundation for future investigation into the mechanism(s) by which NRP/B may play pivotal roles in activating Nrf2-dependent ARE-driven genes in response to oxidative stressinduced damage in NRP/B-expressing cells and tissues.
In conclusion, in the present study, we demonstrate that NRP/B plays an important role in activating Nrf2-mediated NQO1 transcription. The failure of NRP/B mutants to activate Nrf2-mediated NQO1 may be associated with human brain tumor development. These findings provide insights into the biological function of NRP/B as a modulator of cellular protection against ROS in human brains. Furthermore, the present study also introduced a new approach to analyse the functional consequences of gene mutations in brain tumor specimens, and may point towards the active involvement of nuclear matrix proteins in oxidative stress responses and cancer.
Materials and methods
DNA constructs
NRP/B mutant clones isolated from human brain tumors were amplified by PCR using pfu DNA polymerase with primers (5 0 -CCGTCGACTCAGTCAGTGTGCATGAG-3 0 ) and (5 0 -CT GCGGCCGCAGAAGGCAGATGTTTCCAG-3 0 ) and subcloned into pCMV/myc/nuc vector (cat. V821-20; Invitrogen, Carlsbad, CA, USA) at SalI and NotI restriction sites. Resultant constructs were designated as NRP/B:WT (wildtype), NRP/B:NSQR (mutant from primary brain tumor specimen: mutation N to S at position 216aa and Q to R at position 463aa), NRP/B:EKCR (mutant from primary brain tumor specimen: mutation E to K at 96aa and C to R at 531aa). The expression of these constructs was analysed by western blotting using anti-Myc or anti-NRP/B (VD2) antibody. To direct the expression of NRP/B in the cytoplasm, NRP/B cDNA was cloned into a pCMV/myc/cyto vector (cat. V820-20) (Invitrogen). The resulting construct was designated NRP/B:WT/Cyt. The GST-Nrf2 construct was generated by amplifying pEGFP-Nrf2 (kind gift from Dr Laurie Zipper) (Zipper and Mulcahy, 2002 ) using sets of primers as follows: 5 0 -GACGGATCCGACTTGGAGCTGCCGCCG-3 0 and 5 0 -GACGAATTCTTATTAGTTTTTCTTAACATC-3 0 . The PCR products were cloned into a modified pGEX-2T vector at BamHI and EcoRI sites, and the constructs were verified by sequencing. The constructs were designated as GST-Nrf2, and its expression was confirmed by induction with isopropyl-D-thiogalactoside in Escherichia coli. DsRedKeap1 was a gift from Dr Manabu Furukawa (Furukawa and Xiong, 2005) . The ARE-Ti-luc promoter construct was kindly provided by Dr William E Fahl (Wasserman and Fahl, 1997) .
Preparation of NRP/B antibody (VD2)
We previously generated several anti-NRP/B antibodies (Kim et al., 1998) . Briefly, COOH terminal of NRP/B was generated by PCR and was inserted into pBlueBacIII baculoviral vector at BamHI and HindIII sites. NRP/B-His6/pBlueBacIII baculovirus was obtained by using a baculovirus expression system. The NRP/B protein was then expressed and purified from Sf-9 cells. Hybridoma-producing anti-NRP/B antibody was raised by conventional PEG fusion technique using spleen cells and PAI-O partner cells. The clones that survived in the HAT medium were screened by ELISA.
Immunohistochemistry
For tissue staining, the GBM and normal brain (normal frontal cortex) specimens were obtained from the Cooperative Human Tissue Network and Beth Israel Deaconess Medical Center. The GBM was diagnosed by neuropathologists. Paraffin-embedded samples were sectioned at 5 mm. Tissue sections were placed on pre-coated slides, dried overnight at 37 1C and stored at 4 1C. For brain tissues, immunohistochemistry staining was performed using anti-NRP/B antibody (VD2) and detected with an ABC Elite kit and 3,3 0 -diaminobenzidine. For conventional histology, the sections were stained with hematoxylin and eosin.
GST pull-down analysis GST-Nrf2 and GST were expressed in E. coli and purified for the binding assay. Cells were lysed and then rotated for 30 min at 4 1C. To remove the nonspecific binding to GST, protein extracts were incubated with glutathione sepharose beads for 1 h and centrifuged. The supernatants were incubated with GST or GST-Nrf2 at room temperature for 1 h. After three washes, the precipitates were subjected to immunoblotting analysis using anti-NRP/B antibody (VD2).
Real-time PCR and RT-PCR analyses
Real-time RT-PCR was performed using Power SYBR Green PCR Master Mix (cat. 4367659; AB Applied Biosystem, Warrington, UK) and primers: NQO1: 5 0 -TGCAGCGGC TTTGAAGAAGAAAGG-3 0 and 5 0 -TCGGCAGGATACT GAAAGTTCGCA-3 0 , and GAPDH: 5 0 -CATGTTCGTCA TGGGTGTGAACCA-3 0 and 5 0 -AGTGATGGCATGGAC TGTGGTCAT-3 0 . For RT-PCR analysis, transcript levels were semiquantified by one-step RT-PCR according to the manufacturer's instructions (cat. 639503; BD Bioscience Clontech, Mountain View, CA, USA) using the primers for NQO1: 5 0 -AGGCTGGTTTGAGCGAGT-3 0 and 5 0 -ATTGAATTCGG GCGTCTGCTG-3 0 . To ensure equal loading, total RNA was amplified with GAPDH primers: 5 0 -GAAGGTGAAGGTCG GAGTC-3 0 and 5 0 -GAAGATGGTGATGGGATTTC-3 0 .
Statistical analysis
Data are presented as the mean±s.d. The Student's t-test and one-way analysis of variance were used to assess the significance of independent experiments. Po0.05 represents the statistical significance.
Abbreviations ARE, antioxidant response element; GST, glutathione S-transferase; H 2 O 2 , hydrogen oxygenase; Keap1, Kelch-like ECH-associated protein; Nrf2, NF-E2-related factor 2; NRP/ B, nuclear restricted protein in brain; NQO1, NAD(P)H:quinine oxidoreductase 1 (nicotinamide quinine oxidoreductase).
